https://www.marketresearchfuture.com/reports/precision-oncology-market-21854

Biomarker discovery is central to the advancement of precision oncology, and ongoing Precision Oncology Market research continues to uncover new molecular signatures associated with treatment response, disease progression, and therapeutic resistance. These biomarkers help clinicians navigate complex cancer behavior and design more accurate treatment plans.

Genomic biomarkers guide the selection of targeted therapies by identifying mutations susceptible to specific drugs. Meanwhile, protein biomarkers offer insights into tumor physiology and metabolic changes, contributing to more refined diagnostic capabilities.

Circulating tumor DNA (ctDNA) biomarkers play a critical role in early detection and real-time disease monitoring. Through liquid biopsy analysis, clinicians can evaluate residual disease, identify emerging resistance patterns, and adjust treatment strategies promptly.

Research efforts also focus on immunotherapy-related biomarkers that predict patient response to immune checkpoint inhibitors. These indicators help determine which patients will benefit most from advanced immune-based treatments, thereby enhancing therapy precision.

Precision Oncology Market research continues to revolutionize how cancer is diagnosed and treated by uncovering deeper insights into the molecular complexity of tumors.